29,020 Shares in Ocular Therapeutix, Inc. $OCUL Bought by Algert Global LLC

Key Points

• Algert Global LLC has acquired a new stake in Ocular Therapeutix, purchasing 29,020 shares valued at approximately $213,000.
• Multiple hedge funds have adjusted their holdings in Ocular Therapeutix, with a total of 59.21% of the stock currently owned by institutional investors.
• Despite Ocular Therapeutix's revenue of $13.46 million for the last quarter, the company reported a loss of ($0.39) earnings per share, which missed analysts' expectations.

Algert Global LLC purchased a new stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 29,020 shares of the biopharmaceutical company's stock, valued at approximately $213,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Vontobel Holding Ltd. bought a new stake in shares of Ocular Therapeutix in the 1st quarter valued at about $79,000. GAMMA Investing LLC increased its stake in Ocular Therapeutix by 6,760.0% during the 1st quarter. GAMMA Investing LLC now owns 8,232 shares of the biopharmaceutical company's stock worth $60,000 after purchasing an additional 8,112 shares in the last quarter. Rhumbline Advisers increased its stake in Ocular Therapeutix by 4.5% during the 1st quarter. Rhumbline Advisers now owns 223,115 shares of the biopharmaceutical company's stock worth $1,635,000 after purchasing an additional 9,514 shares in the last quarter. ProShare Advisors LLC increased its stake in Ocular Therapeutix by 32.8% during the 4th quarter. ProShare Advisors LLC now owns 51,270 shares of the biopharmaceutical company's stock worth $438,000 after purchasing an additional 12,669 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its stake in Ocular Therapeutix by 82.9% during the 4th quarter. Ameriprise Financial Inc. now owns 89,772 shares of the biopharmaceutical company's stock worth $767,000 after purchasing an additional 40,700 shares in the last quarter. 59.21% of the stock is owned by institutional investors.

Insider Transactions at Ocular Therapeutix

In other news, insider Pravin Dugel sold 21,494 shares of Ocular Therapeutix stock in a transaction on Monday, August 25th. The stock was sold at an average price of $12.04, for a total transaction of $258,787.76. Following the completion of the sale, the insider owned 3,227,244 shares of the company's stock, valued at approximately $38,856,017.76. This trade represents a 0.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jeffrey S. Heier sold 3,063 shares of Ocular Therapeutix stock in a transaction on Monday, August 25th. The stock was sold at an average price of $12.04, for a total value of $36,878.52. Following the sale, the insider directly owned 259,911 shares of the company's stock, valued at $3,129,328.44. This represents a 1.16% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 29,453 shares of company stock valued at $354,614. 2.30% of the stock is currently owned by corporate insiders.

Ocular Therapeutix Stock Performance

Ocular Therapeutix stock traded down $0.31 during mid-day trading on Friday, hitting $12.21. 2,070,425 shares of the company's stock traded hands, compared to its average volume of 2,053,955. The firm has a 50 day simple moving average of $11.30 and a two-hundred day simple moving average of $8.85. Ocular Therapeutix, Inc. has a fifty-two week low of $5.78 and a fifty-two week high of $12.91. The stock has a market cap of $2.12 billion, a price-to-earnings ratio of -9.54 and a beta of 1.49. The company has a debt-to-equity ratio of 0.23, a current ratio of 10.10 and a quick ratio of 10.02.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.04). Ocular Therapeutix had a negative net margin of 382.51% and a negative return on equity of 71.92%. The business had revenue of $13.46 million for the quarter, compared to analyst estimates of $13.12 million. During the same period in the prior year, the business earned ($0.26) EPS. The company's revenue for the quarter was down 17.7% compared to the same quarter last year. On average, research analysts expect that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently issued reports on OCUL. Scotiabank lowered their target price on Ocular Therapeutix from $22.00 to $20.00 and set a "sector outperform" rating for the company in a research note on Wednesday, August 6th. Needham & Company LLC raised their price target on shares of Ocular Therapeutix from $14.00 to $15.00 and gave the stock a "buy" rating in a research note on Tuesday, August 5th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $15.00 price target on shares of Ocular Therapeutix in a research note on Thursday, May 29th. Five equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $17.20.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.